Archive

Successful transplant of porcine heart into adult human with end-stage heart disease

In a first-of-its-kind surgery, a 57-year-old patient with terminal heart disease received a successful transplant of a genetically-modified pig heart and is still doing well three days later…. read more.

Stem cell therapy as potential glaucoma treatment

Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world’s second leading cause of blindness…. read more.

Transplants for alcohol-related liver inflammation surge during pandemic

The increased number of deceased donor liver transplants related to alcoholic hepatitis — up more than 50 percent over predicted numbers — was associated with rising alcohol sales…. read more.

External-beam radiation therapy underused for people with liver cancer awaiting transplant

First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.

Study identifies a major role for immune cells called natural killer cells in organ rejection

Immune cells called natural killer cells contribute to organ rejection after transplantation because they miss “self” proteins on donor cells, according to a study appearing in an upcoming… read more.

Incyte announces positive phase III REACH3 study data published in NEJM for ruxolitinib in chronic graft-versus-host disease

Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.

Transplantation, Consolidation and Maintenance

  Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

ICML 2017: The role of stem cell transplantation for lymphoma in 2017

By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.

BSH 2017: Plenary debate: Allogeneic transplantation should be considered for selected young patients

Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.

EHA 2016: Professor Kwee Yong (London) and Dr Mark Cook (Birmingham) share EHA highlights that will affect practice in the UK, including excitement around daratumumab and where research in the molecular stratification of disease is guiding practice. Professor Sagar Lonial (Atlanta) shares his highlights of EHA and ASCO, including data confirming the benefit of maintenance therapy and of transplant, and Professor Roman Hajek (Ostrava) gives a reality check on what the new data means for patients and haematolgists.